ketanserin has been researched along with Chronic Kidney Failure in 8 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketanserin is an anti-hypertensive drug with an ability to reduce blood pressure variability (BPV) in acute experiments in spontaneously hypertensive rats (SHRs)." | 1.32 | Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. ( Du, WM; Liu, JG; Miao, CY; Shen, FM; Su, DF; Yang, XQ, 2003) |
| " In both dialysis and non-dialysis patients the terminal half-life of ketanserin (mean +/- s." | 1.28 | Ketanserin pharmacokinetics in patients with renal failure. ( Barendregt, JN; Tjandra, YI; Van Der Hoeven, JG; Van Oene, JC; Van Peer, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, WM | 1 |
| Miao, CY | 1 |
| Liu, JG | 1 |
| Shen, FM | 1 |
| Yang, XQ | 1 |
| Su, DF | 1 |
| Borawski, J | 3 |
| Mazerska, M | 3 |
| Pawlak, K | 3 |
| Myśliwiec, M | 4 |
| Azzadin, A | 1 |
| Mysliwiec, J | 1 |
| Wollny, T | 1 |
| Buczko, W | 1 |
| Barendregt, JN | 1 |
| Van Peer, A | 1 |
| Van Der Hoeven, JG | 1 |
| Van Oene, JC | 1 |
| Tjandra, YI | 1 |
| Yamakado, M | 1 |
| Nagano, M | 1 |
| Umezu, M | 1 |
| Tagawa, H | 1 |
| Kiyose, H | 1 |
| Zazgornik, J | 1 |
| Scholz, N | 1 |
| Kuska, J | 1 |
| Minar, E | 1 |
1 trial available for ketanserin and Chronic Kidney Failure
| Article | Year |
|---|---|
Ketanserin lowers erythropoietin concentration in hemodialyzed patients treated with the hormone.
Topics: Adult; Aged; Antihypertensive Agents; Bleeding Time; Blood Platelets; Blood Pressure; Erythrocyte Co | 1995 |
7 other studies available for ketanserin and Chronic Kidney Failure
| Article | Year |
|---|---|
Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Female; Hypertension; Hypertrophy, Left Ventricular; Ketanserin; Kidney Fai | 2003 |
[Ketanserin decreases erythropoietin concentration in hemodialyzed patients on rHuEPO therapy].
Topics: Adolescent; Adult; Blood Pressure; Erythrocyte Count; Erythropoiesis; Erythropoietin; Female; Hemogl | 1994 |
Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats.
Topics: Anemia; Animals; Blood Platelets; Endothelium, Vascular; Erythropoietin; Hypertension; Ketanserin; K | 1995 |
Ketanserin and erythropoiesis in hemodialysis patients with polycystic kidneys.
Topics: Adult; Erythrocyte Count; Erythropoiesis; Erythropoietin; Humans; Ketanserin; Kidney Failure, Chroni | 1996 |
Ketanserin pharmacokinetics in patients with renal failure.
Topics: Adult; Aged; Blood Proteins; Female; Half-Life; Humans; Ketanserin; Kidney Failure, Chronic; Male; M | 1990 |
Role of endogenous serotonin in the regulation of blood pressure in patients with chronic renal failure.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Ketanserin; Kidney Failure, Chronic; Male; Middle Aged; | 1988 |
Plasma concentrations of ketanserin in chronic hemodialysed patients.
Topics: Adult; Blood Pressure; Humans; Hypertension; Ketanserin; Kidney Failure, Chronic; Kinetics; Middle A | 1986 |